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Transforming growth factor b (TGFb) is overexpressed in advanced can-
cers and promotes tumorigenesis by inducing epithelial–mesenchymal tran-
sition (EMT), which enhances invasiveness and metastasis. Although we
previously reported that EMT could be induced by increasing CK2 activity
alone, it is not known whether CK2 also plays an essential role in TGFb-
induced EMT. Therefore, in the present study, we investigated whether
TGFb signaling could activate CK2 and, if so, whether such activation is
required for TGFb-induced EMT. We found that CK2 is activated by
TGFb treatment, and that activity peaks at 48 h after treatment. CK2 acti-
vation is dependent on TGFb receptor (TGFBR) I kinase activity, but
independent of SMAD4. Inhibition of CK2 activation through the use of
either a CK2 inhibitor or shRNA against CSNK2A1 inhibited TGFb-
induced EMT. TGFb signaling decreased CK2b but did not affect CK2a
protein levels, resulting in a quantitative imbalance between the catalytic a
and regulatory b subunits, thereby increasing CK2 activity. The decrease in
CK2b expression was dependent on TGFBRI kinase activity and the ubiq-
uitin–proteasome pathway. The E3 ubiquitin ligases responsible for TGFb-
induced CK2b degradation were found to be CHIP and WWP1. Okadaic
acid (OA) pretreatment protected CK2b from TGFb-induced degradation,
suggesting that dephosphorylation of CK2b by an OA-sensitive phos-
phatase might be required for CK2 activation in TGFb-induced EMT. Col-
lectively, our results suggest CK2 as a therapeutic target for the prevention
of EMT and metastasis of cancers.
1. Introduction
Transforming growth factor b (TGFb) is a potent
pleiotropic cytokine that regulates cell growth/differen-
tiation, cell motility, extracellular matrix production,
angiogenesis and cellular immune responses (Derynck
et al., 2001; Dumont and Arteaga, 2003). TGFb has
three isoforms, TGFb1, TGFb2 and TGFb3, whose
specific roles have been revealed by knockout mouse
studies (Dickson et al., 1995; Proetzel et al., 1995; San-
ford et al., 1997). TGFb signaling is mediated through
SMAD and non-SMAD pathways to regulate tran-
scription, translation, microRNA biogenesis, protein
synthesis and post-translational modifications (Frey
and Mulder, 1997; Hata and Davis, 2009; Hussey
et al., 2011; Mu et al., 2012; Park et al., 2004; Yu
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et al., 2002). TGFb binds to TGFb type II receptor
(TGFBRII) containing a constitutively active serine/
threonine kinase domain. Ligand binding induces
receptor complex formation between TGFBRII and
TGFb type I receptor (TGFBRI), inducing the phos-
phorylation and activation of TGFBRI by TGFBRII.
In the canonical SMAD pathway, phosphorylated and
activated TGFBRI recruits and phosphorylates recep-
tor-regulated SMAD (R-SMAD) (Shi and Massague,
2003). Phosphorylated R-SMADs form complexes with
SMAD4 and translocate into the nucleus, where they
activate or repress the expression of TGFb-responsive
genes in a cell type- and context-dependent manner
(Koinuma et al., 2009; Massague, 2008). In the non-
SMAD pathways, TGFb activates p38 MAPK, p42/
p44 MAPK, c-Src, m-TOR, RhoA, RAS, PI3K/Akt,
protein phosphatase 2A (PP2A)/p70S6K and JNK-
MAPK (Hong et al., 2011; Kang et al., 2009; Mu
et al., 2012).
TGFb inhibits cell cycle progression and proliferation
in benign cells in the early stages of tumorigenesis (Prin-
cipe et al., 2014). TGFb overexpression is demonstrated
in many cancers (Bruna et al., 2007; Chod et al., 2008;
Labidi et al., 2010; Langenskiold et al., 2008; Shariat
et al., 2008) and is related to a poor prognosis (Tsushima
et al., 1996; Wikstrom et al., 1998). It induces tumor pro-
gression, including enhancement of tumor cell prolifera-
tion, invasion and metastasis (Akhurst and Derynck,
2001; Inman, 2011; Langenskiold et al., 2008; Massague,
2008; Padua and Massague, 2009; Pasche, 2001). The
three most common mechanisms underlying TGFb-
mediated tumor progression are epithelial–mesenchymal
transition (EMT), increased invasiveness and metastasis,
and immunosuppression (Haque and Morris, 2017).
EMT is a biological process in which cells lose
epithelial characteristics; however, they also acquire
mesenchymal characteristics through multiple bio-
chemical changes (Kalluri and Neilson, 2003). The
transitioned cells are characterized by loss of epithelial
cell polarity, cell–cell junction disassembly and
increased cell motility (Ikenouchi et al., 2003). EMT
occurs in many biological processes, such as implanta-
tion, embryogenesis, organ development, wound heal-
ing, tissue regeneration, organ fibrosis and tumor
progression (Kalluri and Weinberg, 2009). The E- to
N-cadherin switch, often occurring during EMT, is the
replacement of E-cadherin expression with N-cadherin
expression (Cavallaro et al., 2002; Christofori, 2003;
Hsu et al., 1996; Li et al., 2001; Scott and Cassidy,
1998; Tang et al., 1994) and a molecular hallmark of
EMT (Kalluri and Weinberg, 2009). Transcriptional
E-cadherin repression is a major molecular mechanism
underlying E-cadherin expression loss during the
cadherin switch (Thiery and Sleeman, 2006). E-cad-
herin transcriptional repressors, whose expression or
activity is regulated by TGFb signaling, include the
Snail superfamily of zinc-finger transcriptional repres-
sors, Snail1 (Batlle et al., 2000; Cano et al., 2000) and
Snail2 (also called Slug) (Bolos et al., 2003; Hajra
et al., 2002), the ZEB family of transcription factors,
ZEB1 (also called TCF8 and dEF1) and ZEB2 [also
called ZFXH1B and SMAD-interacting protein 1
(SIP1)] (Comijn et al., 2001; Eger et al., 2005), bHLH
factors, Twist1, E47 (also called TCF3) and TCF4
(also called E2-2)(Perez-Moreno et al., 2001; Yang
et al., 2004).
Protein kinase CK2 is a constitutively active, growth
factor-independent serine/threonine-protein kinase with
key roles in cell cycle regulation, cellular differentiation,
proliferation and apoptosis regulation (Ahmad et al.,
2005; Shin et al., 2005; Song et al., 2000). Changes in
CK2 expression or activity have been reported in many
cancers (Kim et al., 2007; Landesman-Bollag et al.,
2001; Scaglioni et al., 2006; Shin et al., 2005) and over-
expression of the catalytic subunit of CK2 can induce
tumorigenesis (Landesman-Bollag et al., 2001). CK2 is
also a positive regulator of Wnt signaling, which is
important for metastasis (Seldin et al., 2005). Recently,
we reported that an increase in CK2 activity induced the
E- to N-cadherin switch (Ko et al., 2012). Although an
increase in CK2 activity could induce the E-to N-cad-
herin switch, it is not known whether CK2 plays a role
in TGFb-induced EMT. Because it is well known that
TGFb induces EMT, the present study aimed to investi-
gate whether TGFb signaling could activate CK2 and
also whether the activation was essential for TGFb-
induced EMT.
2. Materials and methods
2.1. Cell culture, reagents and plasmid
A human non-small cell lung cancer (NSCLC) cell line,
A549 was cultured in Roswell Park Memorial Institute
1640 medium (Gibco Laboratories, Gaithersburg, MD,
USA), supplemented with 10% fetal bovine serum
(Gibco), 100 lgmL1 streptomycin (Gibco), and
100 UmL1 penicillin (Gibco). Human embryonic kid-
ney (HEK) 293 cells were cultured in Dulbecco’s modi-
fied Eagle’s medium (Gibco). All cells were cultured at
37 °C in 5% CO2. The CK2 inhibitor, emodin (Sigma-
Aldrich, St Louis, MO, USA), and the reversible cell-
permeable proteasome inhibitor, MG132 (Sigma-
Aldrich), were prepared in 20 mM stock with dimethylsul-
foxide (Sigma-Aldrich). The TGFBRI-specific inhibitor,
SB431542 (Sigma-Aldrich), was prepared in 10 mM stock
1812 Molecular Oncology 12 (2018) 1811–1826 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
CK2 activation in TGFb-induced EMT S. Kim et al.
with dimethylsulfoxide. The protein phosphatase inhibi-
tor, okadaic acid (OA; Sigma-Aldrich), was prepared in
10 lM stock with dimethylsulfoxide. TGFb (R&D Sys-
tems, Minneapolis, MN, USA) was prepared in
10 lgmL1 stock. pCMV5 TBRI-His was a gift from
Joan Massague (Addgene plasmid # 19161). pCMV5B-
TGFb receptor I K232R was a gift from Jeff Wrana
(Addgene plasmid # 11763). p3TP-Lux (Wrana et al.,
1992), containing the plasminogen activator inhibitor-1
(PAI-1) gene TGFb response element and three collage-
nase I AP-1 repeats in front of luciferase, was a gift from
Joan Massague & Jeff Wrana (Addgene plasmid #
11767). pCMV5B-Flag-Smurf1 wt was a gift from Jeff
Wrana (Addgene plasmid # 11752), pCMV5B-Flag-
Smurf2 wt was a gift from Jeff Wrana (Addgene plasmid
# 11746), p4489 Flag-betaTrCP was a gift from Peter
Howley (Addgene plasmid # 10865), pcDNA3-HA2-
ROC1 was a gift from Yue Xiong (Addgene plasmid #
19897) and pCI HA NEDD4 was a gift from Joan Mas-
sague (Addgene plasmid # 27002). pCMV-Tag3B-
WWP1-myc was kindly provided by Dr Ceshi Chen
(Kunming Institute of Zoology). Flag-tagged pCMV-
Tag2C-WWP1 was kindly provided by Dr Hyeon Soo
Kim (Lee et al., 2013).
2.2. Western blot analysis
Western blot analysis was performed as described previ-
ously (Ko et al., 2012). Blotted membranes were
immunostained with antibodies specific for the follow-
ing antigens: HA tag (Covance, New York, NY, USA);
Myc tag, Smad2/3, phosphoSmad2/3 and carboxyl ter-
minus of Hsc70-interacting protein (CHIP; Cell Signal-
ing, Danvers, MA, USA); Flag tag and b-actin (Sigma-
Aldrich); 6 9 His tag and CK2b (R&D Systems); E-
cadherin and N-cadherin (Thermo Fisher Scientific,
Rockford, IL, USA); WW domain containing E3 ubiq-
uitin protein ligase 1 (WWP1) (ProteinTech Group,
Inc., Chicago, IL, USA); CK2a (EMD Millipore,
Burlington, MA, USA); and HDAC I, Smad4 and
vimentin (Santa Cruz Biotechnology Inc., Santa Cruz,
CA, USA). The secondary antibodies were goat anti-
rabbit IgG peroxidase, goat anti-mouse IgG horseradish
peroxidase (Thermo Fisher Scientific) and donkey anti-
sheep IgG horseradish peroxidase (R&D Systems). Sig-
nals were developed using Lumi-Light Western Blotting
Substrate (Roche Diagnostics, Indianapolis, IN, USA)
in accordance with the manufacturer’s instructions.
2.3. In vitro kinase assay
To evaluate intracellular CK2 activity, an in vitro
kinase assay was performed as described previously
with slight modification (Scaglioni et al., 2006). Bacte-
rially expressed GST-CS (CK2 Substrate; GST-
RRRDDDSDDD) (3 lg) was incubated with glu-
tathione-Sepharose 4B beads for 60 min, and washed
twice with kinase buffer (4 mM Mops, pH 7.2, 5 mM
b-glycerophosphate, 1 mM EGTA, 200 lM sodium
orthovanadate, and 200 lM dithiothreitol). The beads
were incubated with 100 lg of cell lysates in a final
volume of 50 lL of kinase reaction buffer (10 lL of
5 9 kinase buffer, 10 lL magnesium/ATP cocktail
[90 lL of 75 mM MgCl2/500 mM ATP and 10 lL
(100 lCi) of [c-32P]-ATP]) for 20 min at 30 °C. The
reactions were stopped by washing twice with 1 9 ki-
nase buffer. The samples were resuspended with 30 lL
of 2 9 SDS/PAGE sample-loading buffer, subjected to
12% SDS/PAGE, stained with Coomassie Brilliant
Blue, and dried on Whatman paper (GE Healthcare
Life Sciences, Little Chalfont, UK). 32P incorporation
was detected by autoradiography.
2.4. shRNA and siRNA
shRNA-mediated knockdown of CSNK2A1 (Ko et al.,
2012) or SMAD4 was performed using the HuSH-plas-
mid system (Origene Technologies Inc., Rockville, MD,
USA). The shRNA sequences tested for SMAD4 knock-
down were: sequence #1: TTCAGGTGGCTGGTCG-
GAAAGGATTTCCT; sequence #2: GCAGCCA
TAGTGAA GGACTGTTGCAGATA; sequence #3:
CCAACATTCCTGTGGCTTCCACAAGTC AG; and
sequence #4: GTCAGGTGCCTTAGTGACCACGCG
GTCTT. We validated all constructs individually and
found that constructs #1 and #2 were effective for
SMAD4 knockdown. Subsequently, we used construct
#1 for SMAD4 knockdown. Mission esiRNA human
STUB1 was purchased from Sigma-Aldrich. Silencer
select pre-designed siRNA targeting human WWP1 (hu-
man; siRNA ID s21788) was purchased from Ambion
(Thermo Fisher Scientific). The cells were transfected
with siRNA using Lipofectamine RNAiMAX (Invitro-
gen/Life Technologies, Carlsbad, CA, USA) in accor-
dance with the manufacturer’s instructions.
2.5. Dual-luciferase reporter assay
The cells were seeded in six-well plates and cotrans-
fected with p3TP-Lux and pRL-TK using ViaFectTM
(Promega Corp., Madison, WI, USA). Twenty-four
hours after transfection, the cells were treated with
TGFb for 24 h, washed with PBS and harvested. Cell
lysates were prepared with 200 lL of Passive Lysis
buffer (Promega). Aliquots (20 lL) of cleared lysate
were analyzed for luciferase activity using a Dual-
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luciferase reporter assay system (Promega). The luci-
ferase activity of p3TP-Lux was normalized to that of
pRL-TK.
2.6. Cell fractionation
The cells were allowed to swell in buffer A comprising
10 mM Hepes (pH 7.9), 10 mM KCl, 0.1 mM EDTA,
1 mM dithiothreiltol, 1 mM phenylmethanesulfonyl flu-
oride, 1 9 protease inhibitor cocktail and 1 mM
sodium orthovanadate. The samples were adjusted to
0.6% Nonidet P-40 (NP-40), and vortexed vigorously
for 10 s. Nuclei were pelleted by centrifugation at
10 000 9 g for 30 s at 4 °C. The supernatants were
collected and used as the cytoplasmic fraction. After
washing the pellets with PBS, they were lysed in buffer
C comprising 20 mM Hepes, pH 7.9, 0.4 M NaCl,
0.1 mM EDTA, 1 mM dithiothreitol, 1 mM phenyl-
methanesulfonyl fluoride, 1 9 protease inhibitor cock-
tail and 1 mM sodium orthovanadate by sonication.
The lysates were cleared by centrifugation at
10 000 9 g for 20 min at 4 °C. The supernatants were
collected and used as the nuclear fraction.
2.7. Immunoprecipitation
The cells were collected and lysed with 1 mL of
immunoprecipitation lysis buffer (50 mM Tris-HCl, pH
7.4, 150 mM NaCl, 0.5% NP-40) with cOmpleteTM pro-
tease inhibitor cocktail (Roche Diagnostics). The cell
lysates were pre-cleared and then incubated with the
appropriate antibodies for 1 h at 4 °C. The antibody–
protein complexes were precipitated with Protein A/G-
Sepharose beads (Santa Cruz Biotechnology Inc.),
washed, and resuspended in 40 lL of SDS/PAGE
loading buffer.
2.8. Site-directed mutagenesis
To generate mutants of CK2b with the autophosphoryla-
tion sites (serine 2, 3, and 4) mutated to non-phosphory-
latable alanine residues or to phosphomimetic glutamic
acids or to generate TGFBRI constitutively active (CA)
mutant (threonine 204 is replaced with aspartic acid),
mutagenesis was performed using a QuikChange site-
directed mutagenesis kit (Stratagene, Cedar Creek, TX,
USA). All mutant constructs were confirmed by DNA
sequencing. The mutagenic primer pairs used to generate
mutants were: CK2b 3E (S2ES3ES4E): forward, 50-
GACGTGAAGATGGAAGAAGAAGAGGAGGTGT
CC-30; reverse, 50-GGACACCTCCTCTTCTTCTTCGA
TCTTCACGTC-30. CK2b 3A (S2A S3AS4A): forward,
50-GACGTGAAGATGGCAGCAGCAGAGGAGGT-
GTCC-30; reverse, 50-GGACACCTCCTCTGCTGCT-
GCCATCTTCACGTC-30. TGFBRI CA: forward, 50-
GAACAATTGCGAGAGATATTGTGTTACAAG-30;
reverse, 50-TCCGTA ACACAATATCTCTCGCAATT-
GTTC-30.
2.9. Cell migration assay
A cell migration assay was conducted using specific
wound-assay chambers purchased from ibidi GmbH
(Munich, Germany). All experiments were performed
in accordance with the manufacturer’s instructions.
2.10. Statistical analysis
Statistical comparisons of groups were performed
using Student’s t-test. P < 0.05 was considered statisti-
cally significant.
3. Results
3.1. CK2 activation was required for
TGFb-induced EMT
An increase in CK2 activity by CK2a overexpression
induced EMT in the cancer cells (Ko et al., 2012) and
TGFb-induced EMT in A549 cells (Kasai et al., 2005).
To investigate whether CK2 was activated during
TGFb treatment, A549 cells were treated with TGFb
and harvested at 0, 24, 48 and 96 h after treatment.
Lysates were prepared, and an in vitro kinase assay
and western blot analysis were performed. CK2 activ-
ity peaked at 48 h after TGFb treatment and the E-to
N-cadherin switch was observed 24 h after TGFb
treatment (Fig. 1A). To examine whether TGFBRI
kinase activity was required for the CK2 activation,
A549 cells were pretreated with the TGFBRI kinase
inhibitor, SB431542. We found that, without TGFBRI
activation, neither the increase in CK2 activity, nor
the cadherin switch occurred (Fig. 1B). To examine
whether the CK2 activation is required for TGFb-
induced EMT, A549 cells were treated with the phar-
macological CK2 inhibitor, emodin, and then with
TGFb for 48 h. In the absence of emodin, A549 cells
changed from a rounded, epithelial morphology to a
spindle and fibroblast-like appearance (Fig. 1C) and
the E- to N-cadherin switch (Fig. 1D) was observed.
However, in the presence of emodin, morphological
changes and cadherin switch were not observed
(Fig. 1C,D). To confirm these results, we generated
stable CSNK2A1 knockdown (CKD) A549 cells. Previ-
ously, we reported that CKD could decrease cellular
CK2 activity (Ko et al., 2012). We found that CKD
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Fig. 1. Requirement of CK2 activation in TGFb-induced EMT. (A) CK2 activation during TGFb-induced EMT. A549 cells were treated with
TGFb for the indicated time periods. Western blot analysis was performed with the indicated antibodies (top) and an in vitro kinase assay
was performed using the same lysates (bottom). GST-CS represents input GST-CS stained with Coomassie Brilliant Blue. 32P-GST-CS
represents phosphorylated GST-CS. (B) Effect of TGFBRI kinase inhibitor on CK2 activation. A549 cells were pretreated or untreated with
SB431542 (10 lM) for 12 h, and then with TGFb for 48 h. Western blot analysis was performed with the indicated antibodies (top) and an
in vitro kinase assay was performed (bottom). (C) Effect of a CK2 inhibitor on the morphology of TGFb-treated cells. A549 cells were
pretreated or untreated with emodin (40 lM) for 12 h and TGFb (5 ngmL1) was added to the media for 48 h. Photographs were taken
using phase contrast microscope. Scale bars = 20 lm. (D) Effect of a CK2 inhibitor on EMT. A549 cells were treated as in (C). Western blot
analysis was performed with the indicated antibodies using b-actin as the loading control for total cell lysates. (E) Effect of CKD on cell
morphology. Scale bars = 50 lm. (F) Effect of CKD on EMT. Control and CKD cells were treated with TGFb for 48 h. Western blot analysis
was performed with the indicated antibodies using b-actin as the loading control for total cell lysates. (G) Effect of CKD on motility of the
cells. Migration assays were performed in the presence or absence of TGFb. The images shown from one experiment are representative of
two experiments. Sscale bars = 200 lm.
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cells showed neither morphological changes (Fig. 1E),
nor the cadherin switch (Fig. 1F) with TGFb treat-
ment. To examine the effect of CKD on motility of
the cells, migration assays were performed. Even in the
presence of TGFb, CKD cells were not motile
(Fig. 1G).
3.2. CK2 activation independent on SMAD4
Because the increase in CK2 activity depended on
TGFBRI kinase activity, we then examined whether
canonical SMAD signaling was required for activation.
To disrupt canonical SMAD signaling, we generated
stable SMAD4-knockdown (SKD) A549 cells using
shRNA. When SKD cells were treated with TGFb,
EMT was induced and CK2 was activated (Fig. 2A).
Next, we examined whether CK2 was required for
SMAD signaling. When CKD cells were treated with
TGFb, SMAD2 was phosphorylated (Fig. 2B, lane 2
vs. lane 4) and SMAD4 was translocated into the
nucleus (Fig. 2C, lane 2 vs. lane 4) even in the absence
of CK2 activation (Fig. 2B, lane 2 vs. lane 4). There
was no difference in p3TP-Lux (Wrana et al., 1992)
luciferase activity between the control and CKD cells
by TGFb treatment (Fig. 2D). Collectively, these
results suggested that CK2 activation and EMT did
not require SMAD4.
3.3. CK2b degradation by TGFb signaling
Because TGFb-induced CK2 activation depended on
TGFBRI kinase activity, TGFBRI CA was used for
TGFb signaling instead of TGFb treatment (Wieser
et al., 1995). Because unbalanced protein levels of
CK2 subunits may drive EMT (Deshiere et al., 2013),
we then examined whether TGFb signaling could alter
the protein level of CK2a or CK2b. Western blot anal-
ysis using lysates from HEK 293 cells cotransfected
with TGFBRI CA and either with CK2a or CK2b
showed that CK2b expression was decreased CK2b
but did not affect CK2a protein levels (Fig. 3A). To
determine the effect of CK2b downregulation on CK2
activity, CSNK2B-knockout (bKO) A549 cells were
generated using the CRISPR/Cas9 gene knockout sys-
tem. Western blot analysis and in vitro kinase assay
showed that with bKO, the E- to N-cadherin switch
was induced (Fig. 3B, top) and CK2 activity was
increased (Fig. 3B, bottom) even in the absence of
Fig. 2. SMAD4 independent CK2 activation. (A) Effect of SKD on CK2 activation. Control or SKD A549 cells were treated, or not, with TGFb
for 48 h. Western blot analysis was performed with the indicated antibodies (top) and an in vitro kinase assay was performed (bottom). (B)
Effect of CKD on TGFb-induced SMAD2 phosphorylation. Control or CKD cells were treated, or not, with TGFb for 48 h. Western blot
analysis was performed with the indicated antibodies (top) and an in vitro kinase assay was performed (bottom). (C) Effect of CKD on TGFb-
induced nuclear localization of SMAD4. Control or CKD cells were treated, or not, with TGFb for 48 h. Cells were fractionated, and western
blot analysis was performed with the indicated antibodies using the nuclear fraction. (D) Effect of CKD on p3TP-lux-promoter activation by
TGFb. The luciferase activity of p3TP-Lux was normalized to that of pRL-TK. Data represent the mean  SD of one experiment performed
in triplicate. Similar results were obtained from two independent experiments.
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TGFb treatment. A nigration assay showed that bKO
cells became motile even without TGFb treatment
(Fig. S1). To confirm the effect of TGFb signaling on
the protein level of CK2a and CK2b, A549 cells were
treated with TGFb for 1, 3, 6, 12 and 24 h. Western
blot analysis confirmed that the protein level of
endogenous CK2a was not altered by TGFb treat-
ment; however, CK2b was decreased by the treatment
(Fig. 3C, top). An in vitro kinase assay using the same
lysates showed that CK2 activity was increased and
Fig. 3. Degradation of CK2b by TGFb signaling. (A) Effect of TGFb signaling on the protein level of each CK2 subunit. HEK 293 cells were
cotransfected with HA-CK2a or Myc-CK2b along with His-TGFBRI CA. Western blot analysis was performed with the indicated antibodies.
(B) Effect of bKO on CK2 activity and EMT. bKO cells were generated using the CRISPR/Cas9 system. Western blot analysis was
performed with the indicated antibodies (top) and an in vitro kinase assay was performed (bottom). (C) Effect of TGFb on the protein levels
of endogenous CK2 subunits and CK2 activity. A549 cells were treated with TGFb for the indicated time periods. Western blot analysis was
performed with the indicated antibodies (top) and an in vitro kinase assay was performed (bottom). (D) TGFBRI kinase activity-dependent
(top) and proteasome-dependent (bottom) CK2b degradation. HEK 293 cells were cotransfected with His-TGFBRI CA or His-TGFBRI KD
along with Myc-CK2b, or cotransfected with His-TGFBRI CA along with Myc-CK2b, followed by MG132 (10 lM) treatment. Western blot
analysis was performed with the indicated antibodies. (E) TGFBRI kinase activity-dependent and proteasome-dependent degradation of
CK2b and EMT. A549 cells were transfected with Myc-CK2b and pretreated with dimethylsulfoxide, SB431542 or MG132 for 12 h. The
cells were treated with TGFb for the indicated time periods. Western blot analysis was performed with the indicated antibodies.
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maintained until 24 h after TGFb treatment (Fig. 3C,
bottom). To examine whether TGFBRI kinase activity
is required for the decrease in CK2b expression,
TGFBRI kinase dead was used (lysine 232 is replaced
with arginine). Unlike TGFBRI CA, TGFBRI kinase
dead did not decrease the protein level of CK2b, indi-
cating that the decrease in the CK2b protein level was
dependent on TGFBRI kinase activity (Fig. 3D, top).
To examine whether CK2b is degraded by the ubiqui-
tin-dependent proteasome pathway, cells cotransfected
with TGFBRI CA and CK2b were treated with
MG132; in the presence of MG132, CK2b was not
degraded by TGFb signaling (Fig. 3D, bottom). To
confirm these results, A549 cells were pretreated with
SB431542 or MG132 before TGFb treatment. In the
absence of SB431542 or MG132, CK2b was rapidly
degraded, and the E- to N-cadherin switch was
induced (Fig. 3E; dimethylsulfoxide). When SB431542
was pretreated, the CK2b was degraded more slowly
than in dimethylsulfoxide treated cells, and the E- to
N-cadherin switch was not induced (Fig. 3E;
SB431542). When MG132 was pretreated, CK2b was
not degraded, and the E- to N-cadherin switch was
not induced (Fig. 3E; MG132).
3.4. CHIP and WWP1 are E3 ubiquitin ligases for
CK2b degradation
Because CK2b is polyubiquitinated in TGFb signaling
(Fig. S2), we examined which E3 ligase (s) is involved
in the ubiquitination of CK2b. Among the E3 ubiquitin
ligases known to be involved in TGFb signaling and
that we used for screening (De Boeck and ten Dijke,
2012), CHIP and WWP1 lowered the CK2b protein
level (Figs S3 and 4A). MG132 protected CK2b from
CHIP- and WWP1-mediated degradation (Fig. 4A)
and CK2b interacted with these E3 ligases (Fig. 4B).
Both CHIP and WWP1 increased CK2b ubiquitination
(Fig. 4C) and, together with TGFb signaling, CHIP
and WWP1 efficiently degraded CK2b (Fig. 4D). To
examine the effect of CHIP or WWP1 knockdown on
the CK2b protein level during TGFb signaling, siRNA
against CHIP or WWP1 was used. The CK2b protein
level was not decreased by TGFb treatment in the
absence of either CHIP or WWP1 expression (Fig. 4E).
3.5. Dephosphorylation-dependent CK2b
degradation
As reported previously (Zhang et al., 2002), CK2b was
autophosphorylated by CK2a and stabilized (Fig. 5A).
To examine whether TGFb signaling could degrade
phosphorylated CK2b, phosphomimetic CK2b 3E
mutant was used. We found that phosphorylated CK2b
was not degraded by TGFb signaling (Fig. 5B). Based
on these results, we assumed that dephosphorylation of
CK2b preceded the degradation of CK2b. Because it
was reported that TGFb signaling could activate OA-
sensitive protein phosphatase (Petritsch et al., 2000),
HEK 293 cells cotransfected with TGFBRI CA and
Myc-CK2b were treated or untreated with 2 nM OA. In
the presence of OA, CK2b was no longer degraded by
TGFb signaling, indicating that the degradation
required the activation of OA-sensitive phosphatase
(Fig. 5C). To confirm these results, A549 cells were pre-
treated or untreated with OA for 12 h and then treated
with TGFb for the indicated time periods. Western blot
analysis showed that OA treatment protected endoge-
nous CK2b from degradation (Fig. 5D). To examine
whether CHIP binds to dephosphorylated CK2b, HEK
293 cells were cotransfected with CHIP and CK2b in
the presence or absence of CK2a or CK2b 3E mutant.
IP and western blot analysis revealed that CHIP could
bind more selectively to unphosphorylated CK2b
(Fig. 5E). CHIP and WWP1 efficiently degraded wt
CK2b but did not degrade CK2b 3E mutant (Fig. 5F).
4. Discussion
The present study shows that TGFb activated CK2
and activation was required for TGFb-induced EMT.
We observed that TGFb signaling decreased the CK2b
Fig. 4. CHIP and WWP1 as E3 ubiquitin ligases for TGFb-induced CK2b degradation. (A) CHIP- and WWP1-mediated degradation of CK2b.
HEK 293 cells were cotransfected with Flag-CHIP and Myc-CK2b (left) or with Flag-WWP1 and Myc-CK2b (right) and then treated or not
with MG132 for 12 h. Western blot analysis was performed with the indicated antibodies. (B) CK2b interaction with CHIP or WWP1. HEK
293 cells were cotransfected with Flag-CHIP and Myc-CK2b (left) or with Flag-WWP1 and Myc-CK2b (right). Immunoprecipitation was
performed using anti-Myc Ab followed by western blot analysis. The expression controls were given in the Input. (C) CHIP- or WWP1-
induced polyubiquitination of CK2b. HEK 293 cells were cotransfected with indicated plasmids and then treated with MG132 for 12 h.
Immunoprecipitation was performed using anti-Myc Ab. Western blot analysis was performed with anti-HA Ab. The expression controls
were given in the Input. (D) CHIP- or WWP1-mediated CK2b degradation during TGFb signaling. HEK 293 cells were cotransfected with
indicated plasmids. Western blot analysis was performed with the indicated antibodies. (E) CHIP- or WWP1-mediated CK2b degradation in
TGFb signaling. A549 cells were transfected with either siRNA against CHIP (left) or siRNA against WWP1 (right) and then treated with
TGFb for the indicated time periods. Western blot analysis was performed with the indicated antibodies.
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protein level, thereby resulting in an imbalance between
the protein levels of the catalytic a and regulatory b
subunits, leading to CK2 activation. This decrease was
TGFBRI kinase activity-dependent and proteasome-
dependent. We also observed that the E3 ubiquitin
ligase involved in CK2b degradation was CHIP, and
that OA-sensitive phosphatase-mediated dephosphory-
lation was required for CHIP-mediated degradation.
Although CK2 is known to be a ligand-independent,
constitutively active serine/threonine kinase, EGF
could activate CK2 (Ackerman et al., 1990; Ji et al.,
2009). Apart from EGF, TGFb also could activate
CK2 (Fig. 1). Although CK2 activity peaked at
50 min post EGF treatment, and returned to baseline
by approximately 120 min (Ackerman et al., 1990),
CK2 activity peaked approximately at 48 h post
TGFb treatment (Fig. 1) suggesting that EGF and
TGFb might operate with different mechanisms for
CK2 activation. Although EGF activated CK2 via
ERK2-mediated CK2a phosphorylation (Ji et al.,
2009), TGFb might activate CK2 by inducing an
imbalance between the levels of catalytic a and regula-
tory b subunits through b subunit degradation (Figs 3
and 4). The results of the present study were supported
by previous studies reporting that the imbalance
between CK2 subunit levels caused by the reduction of
b regulatory subunit is linked to increase in molecular
target levels related to EMT in tissue samples from
breast cancer patients, and that CK2b-depleted epithe-
lial cells exhibited EMT-like morphological changes,
as well as enhanced migration and anchorage-indepen-
dent growth (Deshiere et al., 2011, 2013). Although
CK2b knockdown could induce EMT phenotye and
strongly elevate TGFb2 expression, blocking the
TGFb signaling pathway did not counteract the EMT
phenotype (Deshiere et al., 2011). Consistent with
these results, we demonstrated that bKO A549 cells
showed EMT phenotypes even in the absence of TGFb
treatment (Figs 3B and S1). We also showed that CK2
activation and TGFb-induced EMT were blocked by
TGFBRI kinase inhibitor (Fig. 1B) and also that
EMT was not induced in the absence of CK2 activa-
tion (Fig. 1D,F) and CK2b downregulation (Fig. 3E),
suggesting that the CK2 activity increase resulting
from downregulation of regulatory CK2b subunit is
required for TGFb-induced EMT. These results sug-
gest that the roles of TGFb signaling in EMT induc-
tion might comprise CK2b degradation-dependent
CK2 activation through a non-canonical SMAD sig-
naling pathway and thus CK2b depleted cells no
longer required TGFb signaling for EMT induction.
An increase in CK2 activity by the overexpression
of CK2a catalytic subunit induced EMT in cancer cells
even in the absence of TGFb-dependent canonical
SMAD signaling (Ko et al., 2012), indicating that
CK2 activation might be necessary and sufficient to
induce EMT. TGFb induces the expression of EMT-
related transcription factors, such as SNAIL1 or ZEB1
through SMAD3-dependent transcription (Hoot et al.,
2008; Postigo, 2003; Vincent et al., 2009). The SMAD
pathway is a canonical TGFb signaling pathway and
involves receptor-regulated SMADs (SMAD2 or
SMAD3) and a common partner SMAD (SMAD4).
Because SMAD4 is a common partner SMAD, SKD
could abolish TGFb-mediated SMAD signaling by
preventing SMAD2 or SMAD3 from forming a com-
plex with SMAD4. In the absence of SMAD4, CK2
was activated and EMT was induced by TGFb, indi-
cating that SMAD4 was not required for TGFb-
induced EMT (Fig. 2A). Our results are supported by
a previous study reporting that SMAD4 is necessary
for TGFb-induced cell-cycle arrest and migration,
although it is not in TGFb-induced EMT (Levy and
Hill, 2005). By contrast to our observations, it was
reported that SMAD4 is indispensable for EMT. RNA
interference-mediated SMAD4 knockdown or expres-
sion of a dominant negative SMAD4 mutant resulted
in preserved E-cadherin expression (Deckers et al.,
2006; Takano et al., 2007). Although the involvement
of SMAD4 in EMT is controversial, we showed that
TGFb could not induce EMT in A549 CKD cells
(Fig. 1E,D) with no alterations in canonical SMAD
signaling (Fig. 2B–D). These results suggest that CK2
activation-dependent downstream signaling events
could be dominant over SMAD signaling-dependent
transcriptional induction of EMT-related transcription
factors in TGFb-induced EMT. CK2 could stabilize
Snail (MacPherson et al., 2010) or b-catenin (Polakis,
2007; Song et al., 2003) by phosphorylation. Stabilized
and nuclear localized b-catenin subsequently upregu-
lates Axin2 expression, upregulated Axin2 shuttles
GSK3b out from the nucleus, and thus nuclear Snail
can be stabilized (Yook et al., 2006). Collectively, we
argued that CK2b subunit might mainly act as a regu-
latory subunit and unbalanced expression of CK2 sub-
units by signaling mediated CK2b depletion could
increase intracellular CK2 activity for downstream sig-
naling event such as EMT.
CK2b is ubiquitinated and degraded through a pro-
teasome-dependent pathway (Zhang et al., 2002). In
the present study, we report that TGFb induced the
ubiquitination and degradation of CK2b (Fig. 4).
Many E3 ubiquitin ligases participate in the ubiquitin-
dependent degradation of molecules involved in TGFb
signaling (De Boeck and ten Dijke, 2012). We screened
some of them and observed that the CK2b protein
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level was decreased by CHIP or WWP1 expression
(Fig. S3). CHIP belongs to the group of really interest-
ing new gene (RING) and RING-related E3 ligases,
and it contains a tetratricopeptide repeat domain
involved in Hsp70 and Hsp90 association (Ballinger
et al., 1999). Hsp90 exists as a complex with Hsc70
and the a and b subunits of CK2 (Suttitanamongkol
et al., 2002). We showed that CHIP interacted with
Fig. 5. Requirement of dephosphorylation in TGFb-induced CK2b degradation. (A) Stabilization of CK2b by CK2a-mediated
autophosphorylation. HEK 293 cells were transfected with or without HA-CK2a along with Myc-CK2b and then treated with cycloheximide
(CHX) for the indicated time periods. Western blot analysis was performed with the indicated antibodies. (B) Protection of CK2b degradation
by phosphorylation. HEK 293 cells were transfected with or without TGFBRI CA along with wt Myc-CK2b (wt), Myc-CK2b 3A (3A) or Myc-
CK2b 3E (3E). Western blot analysis was performed with the indicated antibodies. (C) OA protection of CK2b degradation by TGFb signaling.
HEK 293 cells were transfected with or without TGFBRI CA along with Myc-CK2b and then treated with OA (2 nM) for 12 h. Western blot
analysis was performed with the indicated antibodies. (D) OA protection of endogenous CK2b degradation by TGFb treatment. A549 cells
were pretreated with OA for 12 h and then treated with TGFb for the indicated time periods. Western blot analysis was performed with the
indicated antibodies. (E) Preferential binding of CHIP to dephosphorylated CK2b. HEK 293 cells were cotransfected with indicated plasmids.
Immunoprecipitation was performed using anti-Myc Ab followed by western blot analysis using indicated antibodies. The expression
controls were given in the Input. (F) Efficient degradation of wt CK2b by CHIP and WWP1. HEK 293 cells were cotransfected with indicated
plasmids. Western blot analysis was performed with the indicated antibodies.
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CK2b (Fig. 4B) and that CHIP preferentially bound
to dephosphorylated CK2b (Fig. 5E). Unlike b-trans-
ducin repeat-containing proteins (b-TrCP), which
specifically ubiquitinate phosphorylated substrates
(Laney and Hochstrasser, 1999), CHIP does not
require post-translational substrate modification for
ubiquitination. WWP1 belongs to the C2-WW-Homo-
logous to E6AP C Terminus (HECT) type E3 ubiqui-
tin ligase family (Verdecia et al., 2003). We showed
that WWP1 interacted with CK2b (Fig. 4B), although
we could not detect preferential binding of WWP1 to
dephosphorylated CK2b (data not shown). Instead, we
observed that both CHIP and WWP1 degraded wt
CK2b but did not degrade CK2 b 3E mutant, suggest-
ing that CHIP and WWP1 might preferentially bind to
dephosphorylated CK2b. Our results were partially
supported by a previous study reporting that dephos-
phorylation induces the ubiquitination and degrada-
tion of FMRP (fragile X mental retardation protein)
in dendrites (Nalavadi et al., 2012).
In non-canonical TGFb signaling, TGFBRI kinase-
dependent activation and interaction of phosphatase 2A
with p70-S6 kinase could result in the dephosphoryla-
tion and inactivation of the kinase, thereby inducing G1
arrest (Petritsch et al., 2000). OA is a potent, selective
inhibitor of protein phosphatases, completely inhibiting
PP2A at 1 nM and PP1 at higher concentrations
(IC50 = 10–15 nM). In the present study, we treated cells
with 2 nM OA and thus PP2A could be completely
inhibited; however, this might not be the case for PP1.
OA treatment protected CK2b from TGFb-induced
degradation (Fig. 5), suggesting that PP2A was the
phosphatase involved in TGFb-induced CK2b degrada-
tion. However, we could not inhibit TGFb-induced
CK2b degradation in the PPP2CA-, PPP2CB- or
PPP2R2A-knockout A549 cells generated using the
CRISPR/Cas9 system (S. Kim & K. Kim, unpublished
observation). Further experiments, including the gener-
ation of PPP2CA and PPP2CB double knockout A549
cells, are required to identify the phosphatase involved
in TGFb-induced CK2b dephosphorylation.
TGFb is highly expressed in many cancers (Fried-
man et al., 1995; Levy and Hill, 2006; Picon et al.,
1998). In advanced cancers, TGFb promotes tumorige-
nesis via EMT induction, and thus cancer cells become
more invasive and metastatic. Sustained TGFb signal-
ing could induce sustained CK2 activation, eventually
resulting in metastasis.
5. Conclusions
In summary, the results of the present study show that
TGFb activated CK2 and activation was required for
TGFb-induced EMT. TGFb signaling decreased CK2b
expression, thereby causing an imbalance between the
protein levels of the catalytic a and regulatory b sub-
units, resulting in CK2 activation. The decrease in
CK2b protein level was dependent on TGFBRI kinase
activity and the ubiquitin-proteasome pathway. The
E3 ubiquitin ligases responsible for TGFb-induced
CK2b ubiquitination were CHIP and WWP1. Dephos-
phorylation of CK2b by OA-sensitive phosphatase
might be required for CK2 activation in TGFb-
induced EMT. Therefore, CK2 could be a good thera-
peutic target for inhibiting metastasis in cancers with
high CK2 activity.
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